Clinical Trial Update: Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

View source ↗

Summary

A completed real-world study evaluated how second-line axitinib (Inlyta) impacts outcomes for patients with metastatic renal cell carcinoma who were treated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)
• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Renal Cell Carcinoma (mRCC) | Status: COMPLETED